These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11265773)

  • 1. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
    Weiser TS; Guo ZS; Ohnmacht GA; Parkhurst ML; Tong-On P; Marincola FM; Fischette MR; Yu X; Chen GA; Hong JA; Stewart JH; Nguyen DM; Rosenberg SA; Schrump DS
    J Immunother; 2001; 24(2):151-61. PubMed ID: 11265773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of MAGE-3 expression in lung and esophageal cancer cells.
    Weiser TS; Ohnmacht GA; Guo ZS; Fischette MR; Chen GA; Hong JA; Nguyen DM; Schrump DS
    Ann Thorac Surg; 2001 Jan; 71(1):295-301; discussion 301-2. PubMed ID: 11216765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NY-ESO-1 may be a potential target for lung cancer immunotherapy.
    Lee L; Wang RF; Wang X; Mixon A; Johnson BE; Rosenberg SA; Schrump DS
    Cancer J Sci Am; 1999; 5(1):20-5. PubMed ID: 10188057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
    Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Pishchik V; Figg WD; Murgo AJ; Steinberg SM
    Clin Cancer Res; 2006 Oct; 12(19):5777-85. PubMed ID: 17020984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
    Klar AS; Gopinadh J; Kleber S; Wadle A; Renner C
    PLoS One; 2015; 10(10):e0139221. PubMed ID: 26447882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
    Bao L; Dunham K; Lucas K
    Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
    Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
    J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
    Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J
    Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
    Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
    Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
    Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
    J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.
    Steiner FA; Hong JA; Fischette MR; Beer DG; Guo ZS; Chen GA; Weiser TS; Kassis ES; Nguyen DM; Lee S; Trepel JB; Schrump DS
    Oncogene; 2005 Mar; 24(14):2386-97. PubMed ID: 15735751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.
    Li B; Zhu X; Sun L; Yuan L; Zhang J; Li H; Ye Z
    Oncotarget; 2014 Nov; 5(21):10791-802. PubMed ID: 25301731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution.
    Bownds S; Tong-On P; Rosenberg SA; Parkhurst M
    J Immunother; 2001; 24(1):1-9. PubMed ID: 11211143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
    Klisovic DD; Katz SE; Effron D; Klisovic MI; Wickham J; Parthun MR; Guimond M; Marcucci G
    Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2390-8. PubMed ID: 12766035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
    Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
    J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
    Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H
    Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.